Antegren BLA Submission For Multiple Sclerosis Could See Approval By Year-End

Biogen Idec and Elan are requesting priority review for the MS submission. Companies are also seeking accelerated approval; BLA is based on one-year data from ongoing AFFIRM and SENTINEL trials.